519 Treatment of peritoneal carcinosis using hyperthermic intraperitoneal perfusion

The peritoneal surface is the second most common anatomical site for recurrence by gastrointestinal and ovarian cancer; 50% of all patients treated for gastric, ovarian or colo-rectal cancer present a “Peritoneal Carcinosis”. 50% of patients with PC die without other metastases. Treatment of PC is controversial. Surgery is usually impractical because of its multiplicity and often microscopic size; systemic chemotherapy (CT) is inefficacious because cytotoxic agents do not penetrate into the peritoneal surface in good concentration; intra-peritoneal CT is inefficacious for the low penetration of drugs into the nodule of carcinosis (not more than 1–3 m) in normothermia. Since 1985 Fujimoto et al . showed that intraperitoneal hyperthermic perfusion (IPHP) combined with CT is effective in treatment of Peritoneal Carcinosis. We treat peritoneal carcinosis with Intraperitoneal Hyperthermic Perfusion with high doses of COOP + MMe. Preliminary results in tern of toxicity and responses are impressive according to the data of the literature. The authors report their experience on this new treatment in a disease considered incurable up today. This work has been supported by AIRC, contribution 1994.